Research programme: ephrin-targeted cancer therapeutics - MedImmuneAlternative Names: EA5; MEDI-543; MEDI-548; MEDI-549
Latest Information Update: 07 Jan 2009
At a glance
- Originator Purdue Research Foundation
- Developer MedImmune
- Class Monoclonal antibodies
- Mechanism of Action Eph family receptor antagonists; EphA2 receptor antagonists; EphB4 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer